Pseudoprogression and pseudoresponse: Challenges in brain tumor imaging

Assessment via MRI is an integral part of the management of primary brain tumors. However, reliance on imaging to determine treatment response is not without its pitfalls. Necrosis is a known late effect of radiation treatment of the brain that can mimic tumor recurrence. It is now appreciated that pseudoprogression, a similar effect, can occur after combined chemoradiotherapy and can occur more quickly and dramatically than after radiation alone. Although several adjunct imaging modalities are under investigation, none is yet widely accepted as being able to distinguish between true progression and pseudoprogression. Conversely, at disease progression, antiangiogenic therapies are frequently used and can have a rapid positive effect on imaging. These changes, increasingly known as “pseudoresponses,” can occur immediately after initiating treatment, making accurate assessment of true tumor response difficult. This article reviews the challenges of brain tumor imaging and its use in assessment of treatment response.

[1]  Denis Lacombe,et al.  Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  Dieta Brandsma,et al.  Incidence of early pseudo‐progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide , 2008, Cancer.

[3]  Susan M. Chang,et al.  Three-dimensional magnetic resonance spectroscopic imaging of histologically confirmed brain tumors. , 2001, Magnetic resonance imaging.

[4]  John Sampson,et al.  Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  Marvin Bergsneider,et al.  Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[6]  Mark E Mullins,et al.  Radiation necrosis versus glioma recurrence: conventional MR imaging clues to diagnosis. , 2005, AJNR. American journal of neuroradiology.

[7]  M Takahashi,et al.  Posttherapeutic intraaxial brain tumor: the value of perfusion-sensitive contrast-enhanced MR imaging for differentiating tumor recurrence from nonneoplastic contrast-enhancing tissue. , 2000, AJNR. American journal of neuroradiology.

[8]  P. Wen,et al.  Bevacizumab for recurrent malignant gliomas , 2008, Neurology.

[9]  Darell D. Bigner,et al.  Phase II Trial of Bevacizumab and Irinotecan in Recurrent Malignant Glioma , 2007, Clinical Cancer Research.

[10]  Tracy T Batchelor,et al.  AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. , 2007, Cancer cell.

[11]  Chen Wei-an,et al.  Differentiation of recurrent astrocytoma from radiation necrosis: a pilot study with 13N-NH3 PET , 2007, Journal of Neuro-Oncology.

[12]  J E Heiserman,et al.  Relative Cerebral Blood Volume Values to Differentiate High-Grade Glioma Recurrence from Posttreatment Radiation Effect: Direct Correlation between Image-Guided Tissue Histopathology and Localized Dynamic Susceptibility-Weighted Contrast-Enhanced Perfusion MR Imaging Measurements , 2009, American Journal of Neuroradiology.

[13]  R. Mirimanoff,et al.  MGMT gene silencing and benefit from temozolomide in glioblastoma. , 2005, The New England journal of medicine.

[14]  Susan M. Chang,et al.  Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Michael A. Finn,et al.  Transient postictal MRI changes in patients with brain tumors may mimic disease progression. , 2007, Surgical neurology.

[16]  T. Cascino,et al.  Response criteria for phase II studies of supratentorial malignant glioma. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  K. Hara,et al.  Noninvasive evaluation of malignancy of brain tumors with proton MR spectroscopy. , 1996, AJNR. American journal of neuroradiology.

[18]  A. Brandes,et al.  MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  C. Eskey,et al.  Diffusion-weighted imaging in the follow-up of treated high-grade gliomas: tumor recurrence versus radiation injury. , 2004, AJNR. American journal of neuroradiology.

[20]  Andrew E. Sloan,et al.  Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma , 2007, Journal of Neuro-Oncology.

[21]  Shigeaki Higashiyama,et al.  Diagnostic Accuracy of 11C-Methionine PET for Differentiation of Recurrent Brain Tumors from Radiation Necrosis After Radiotherapy , 2008, Journal of Nuclear Medicine.

[22]  R. Mirimanoff,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[23]  T. Cloughesy,et al.  MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy , 2006, Neurology.

[24]  B. Drayer,et al.  Differentiating recurrent tumor from radiation necrosis: time for re-evaluation of positron emission tomography? , 1998, AJNR. American journal of neuroradiology.

[25]  P Van Tassel,et al.  Malignant gliomas: MR imaging spectrum of radiation therapy- and chemotherapy-induced necrosis of the brain after treatment. , 2000, Radiology.

[26]  Wei Chen Clinical Applications of PET in Brain Tumors* , 2007, Journal of Nuclear Medicine.

[27]  R. Gonzalez,et al.  Clinical and radiographic features of peritumoral infarction following resection of glioblastoma , 2006, Neurology.

[28]  T. Mikkelsen,et al.  A phase II, randomized, non-comparative clinical trial of the effect of bevacizumab (BV) alone or in combination with irinotecan (CPT) on 6-month progression free survival (PFS6) in recurrent, treatment-refractory glioblastoma (GBM) , 2008 .